Evogene (EVGN) EBT (2012 - 2026)
Evogene (EVGN) posted EBT of -$5.9 million for Q1 2026, down 10.64% sequentially from -$5.3 million in Q4 2025, and down 210.35% YoY from $5.4 million in Q1 2025.
Evogene (EVGN) EBT (2012 - 2026) Analysis & Trends
Evogene has reported EBT for 15 years, with the latest figure at -$5.9 million in Q1 2026.
- Quarterly EBT fell 210.35% year-over-year to -$5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.5 million (down 43.3% YoY) and the FY2025 annual result came in at -$13.5 million, up 8.85% from the prior year.
- EBT fell to -$5.9 million in Q1 2026 per EVGN's latest filing, from -$5.3 million in the prior quarter.
- Over five years, EBT peaked at $990000.0 in Q4 2024 and troughed at -$9.7 million in Q2 2022.
- A 5-year average of -$5.3 million and a median of -$5.3 million in 2025 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT soared 113.49% in 2024, then plunged 639.19% in 2025.
- Over 5 years, EBT stood at -$3.8 million in 2022, then sank by 94.41% to -$7.3 million in 2023, then jumped by 113.49% to $990000.0 in 2024, then slumped by 639.19% to -$5.3 million in 2025, then slipped by 10.64% to -$5.9 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$5.9 million, -$5.3 million, and -$2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -5.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.91 Mn |
| Dec 31, 2025 | -5.34 Mn |
| Sep 30, 2025 | -2.73 Mn |
| Jun 30, 2025 | -3.53 Mn |
| Mar 31, 2025 | -1.90 Mn |
| Dec 31, 2024 | 990,000.00 |
| Sep 30, 2024 | -6.75 Mn |
| Jun 30, 2024 | -4.55 Mn |
| Mar 31, 2024 | -3.85 Mn |
| Dec 31, 2023 | -7.34 Mn |
| Sep 30, 2023 | -3.86 Mn |
| Jun 30, 2023 | -7.76 Mn |
| Mar 31, 2023 | -7.03 Mn |
| Dec 31, 2022 | -3.78 Mn |
| Sep 30, 2022 | -7.16 Mn |
| Jun 30, 2022 | -9.72 Mn |
| Mar 31, 2022 | -9.10 Mn |
| Dec 31, 2021 | -8.09 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Jun 30, 2021 | -6.90 Mn |